Hajime Sasaki

Hajime Sasaki

Auto-generated profile, based on publicly available information

Hajime Sasaki

Department of Kidney Transplant Surgery Sapporo City General Hospital Sapporo Japan

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 April 2023 in Science Translational Medicine
Verified
Journal Article
Closed access
HSHajime Sasaki
Hajime Sasaki
THTakayuki Hirose
Takayuki Hirose
TOTetsu Oura
Tetsu Oura
RORyo Otsuka
Ryo Otsuka
IRIvy Rosales
Ivy Rosales
TKTatsuo Kawai
Tatsuo Kawai
Hematopoietic stem cell transplantation (HSCT) has many potential applications beyond current standard indications, including treatment of autoimmune disease, gene therapy, and transplant tolerance induction. However, severe myelosuppression and other toxicities after myeloablative conditioning regimens have hampered wider clinical use. To achieve donor hematopoietic stem cell (HSC) engraftment, it appears essential to establish niches for the donor HSCs by depleting the host HSCs. To date, this has been achievable only by nonselective treatments such as irradiation or chemotherapeutic drugs. An approach that is capable of more selectively depleting host HSCs is needed to widen the clinical application of HSCT. Here, we show in a clinically relevant nonhuman primate model that selective inhibition of B cell lymphoma 2 (Bcl-2) promoted hematopoietic chimerism and renal allograft tolerance after partial deletion of HSCs and effective peripheral lymphocyte deletion while preserving myeloid cells and regulatory T cells. Although Bcl-2 inhibition alone was insufficient to induce hematopoietic chimerism, the addition of a Bcl-2 inhibitor resulted in promotion of hematopoietic chimerism and renal allograft tolerance despite using only half of the dose of total body irradiation previously required. Selective inhibition of Bcl-2 is therefore a promising approach to induce hematopoietic chimerism without myelosuppression and has the potential to render HSCT more feasible for a variety of clinical indications.

2 August 2023 in Nephron
Verified
Journal Article
Open access
PDF file
SISari Iwasaki
Sari Iwasaki
KTKenta Takahashi
Kenta Takahashi
HKHarutaka Katano
Harutaka Katano
TSTadaki Suzuki
Tadaki Suzuki
HSHajime Sasaki
Hajime Sasaki
TTTakahiro Tsuji
Takahiro Tsuji
Renal transplant recipients are at increased risk for the development of a malignant neoplasm. Polyomavirus-associated urothelial carcinoma is a rare tumor that occurs in renal transplant recipients, with approximately 41 cases reported since 2002. It accounts for 27–31% of all post-transplant urothelial carcinomas and develops at an average of 8.5 years after transplantation. Histologically, it shows high-grade urothelial carcinoma (95.1%) with a high frequency of glandular differentiation and micropapillary structures (58.5%) and positive immunohistochemistry for polyomavirus large T antigen, p53 (92.9%), and p16 (100%). We encountered a case of BK polyomavirus (BKPyV)-associated urothelial carcinoma of the bladder diagnosed 54 months after kidney transplantation. Histologically, it was a high-grade urothelial carcinoma with micropapillary features, and immunohistochemically, it was diffusely positive for polyomavirus large T antigen, p16, and p53. BKPyV DNA and mRNA for BKPyV large T antigen have been identified in tissues using real-time polymerase chain reaction. The same sequence of the BKPyV VP1 genome hypervariable region was detected in both transplanted kidney tissue with polyomavirus nephropathy and urothelial carcinoma tissue, suggesting that polyomavirus-associated urothelial carcinoma developed in a background of persistent polyomavirus nephropathy. This case showed typical histological features and was detected and treated at an earlier stage than has been reported. It is important to keep in mind that polyomavirus-associated urothelial carcinoma can develop early after transplantation and might be associated with polyomavirus nephropathy. Because of its rapidly progressive nature, careful follow-up with urine cytology and cystoscopy is necessary. We report this case with a literature review.

12 June 2023 in International Journal of Urology
Verified
Journal Article
Closed access
HSHajime Sasaki
Hajime Sasaki
TTTatsu Tanabe
Tatsu Tanabe
TTTakahiro Tsuji
Takahiro Tsuji
KHKiyohiko Hotta
Kiyohiko Hotta


17 November 2023 in Clinical Transplantation
Verified
Journal Article
Closed access
YTYusuke Takada
Yusuke Takada
TTTatsu Tanabe
Tatsu Tanabe
HSHajime Sasaki
Hajime Sasaki
TTTakashi Tsujimoto
Takashi Tsujimoto
KHKiyohiko Hotta
Kiyohiko Hotta
HHHiroshi Harada
Hiroshi Harada

11 September 2025 in Nephron
Verified
Journal Article
Closed access
TTTatsu Tanabe
Tatsu Tanabe
HSHajime Sasaki
Hajime Sasaki
YSYutaka Shiono
Yutaka Shiono
TSToyoshi Seito
Toyoshi Seito
KUKazuhiro Ujihashi
Kazuhiro Ujihashi
KHKiyohiko Hotta
Kiyohiko Hotta
Introduction: High-dose intravenous immunoglobulin (H-IVIg) has been used as a desensitization therapy for donor-specific anti-HLA antibody (DSA)-positive kidney transplant recipients in Japan since 2019. This study reports the clinical and pathological outcomes of patients who received H-IVIg at Sapporo City General Hospital. Methods: This study included 7 patients who underwent kidney transplantation at our hospital and received H-IVIg as pretransplant desensitization therapy. At our institution, H-IVIg is indicated for patients with a history of sensitization, such as prior blood transfusion, pregnancy, or organ transplantation, and who tested positive in a flow cytometry crossmatch (FCXM) before transplantation. The recipients (mean age: 55.2 ± 11 years) included one male and six females. The donors (mean age: 62.8 ± 8.8 years) included five males and two females. All were living donor transplants, with four cases involving spousal donation. We assessed the immunological status before and after desensitization and retrospectively analyzed kidney function, anti-donor antibody status, and pathological findings. Results: Before desensitization, 6 patients were FCXM-T positive, and all were FCXM-B positive. After desensitization, 3 patients converted to FCXM-T negative; however, all remained FCXM-B positive. The Luminex single antigen test was positive in 4 patients before desensitization; one converted to negative, while one initially negative patient became positive. Consequently, 4 patients remained DSA positive at transplantation. Three patients experienced acute rejection within 1 month: one had antibody-mediated rejection (ABMR), and two had T-cell-mediated rejection. All patients responded to antirejection therapy, preserving their graft function. At 36 months of follow-up, all the patients survived with functional grafts. Pathological findings revealed early rejection in 3 patients, who later developed chronic ABMR. The remaining 4 patients did not experience rejection episodes. Conclusion: The H-IVIg regimen facilitates kidney transplantation in immunologically high-risk recipients. However, the risk of early postoperative rejection and the potential development of chronic ABMR necessitate careful posttransplant monitoring.